Diana Ernst, RPh

In immunocompromised individuals, the use of contaminated product could potentially lead to life-threatening infections.

This age group is now eligible to receive the booster dose at least 2 months after they complete primary vaccination with 3 doses of the monovalent vaccine.

Results showed a significantly greater proportion of patients treated with tapinarof cream achieved vIGA-AD success compared with vehicle cream.

Recent data show that the product is unlikely to be active against currently circulating SARS-CoV-2 variants.

The approval was based on data from the KEYNOTE-091 trial.

Odactra is an allergen extract indicated as immunotherapy for the treatment of HDM-induced allergic rhinitis.

The guidelines were developed by a multidisciplinary workgroup.

The preliminary safety signal was identified by the CDC’s Vaccine Safety Datalink.

Results showed vaccine efficacy of 83.7% against RSV-LRTD, defined by 2 or more symptoms.

The semi-quantitative test uses a whole blood sample to assess cellular host response by analyzing the biophysical properties of white blood cells.

As part of the Choosing Wisely campaign, the American Academy of Pediatrics (AAP) has released a new list of 5 tests and procedures commonly ordered in pediatric emergency medicine that physicians and patients should question. Choosing Wisely is an American Board of Internal Medicine (ABIM) Foundation initiative that aims to promote discussions between clinicians and…

The guidance provides steps to address the potential for cross-contamination.

The vote was mixed when the data was reviewed for younger patients.

The primary endpoint of the study was exercise capacity, as measured by the change from baseline in 6-minute walk distance at 24 weeks.

Intranasal epinephrine was found to be absorbed quicker.

A treatment regimen that includes remdesivir plus the JAK inhibitor baricitinib is being evaluated in hospitalized adults with COVID-19.

The FDA has issued EUA for TaqPath SARS-CoV-2 Assay and Sofia 2 SARS Antigen FIA test, 2 new COVID-19 diagnostics that allow for faster testing.

A phase 2 study of Moderna’s vaccine candidate for COVID-19, mRNA-1273, is expected to start shortly following the Food and Drug Administration’s review of the Company’s Investigational New Drug application.